Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4645 Radio-guided surgery in use for treatment of early relapse in small intestine neuroendocrine tumours

Introduction: Surgery is the only definitive therapy for neuroendocrine tumours (NET). In number of small intestine NET first symptom is ileus or perforation, lifesaving surgical procedures applied. Such cases have significant risk of recurrence.

Conference:

Presenting Author: Hajac �

Authors: Hajac L, Szewczyk K, Piwkowski P, Chowaniec Z, Mazurak J,

Keywords: radio guided surgery, Neuroendocrine tumour, early relapse,

#4641 Case series: Tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

Introduction: Tuberous sclerosis (TSC) is an autosomal dominant condition which can increase the risk of pancreatic neuroendocrine tumours (PanNETs) (1). Patients with TSC undergo screening for renal tumours which may include pancreatic imaging (2). There are currently no screening guidelines for PanNETs in patients with TSC.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: Pancreas neuroendocrine tumour, Tuberous sclerosis,

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4620 Impact of the extent of surgical resection on the development of post-operative diabetes in patients undergoing distal pancreatectomy for non-functioning pancreatic neuroendocrine tumours (NF-PanNET)

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are often indolent neoplasms. Surgery is the primary curative approach for localised non-functioning (NF) PanNETs, but it poses a risk of long-term complications, such as diabetes, impacting quality of life.

Conference:

Presenting Author:

Authors: Battistella A, Partelli S, Guccinelli E, Prato F, Andreasi V,

Keywords: Pan NET, distal pancreatectomy, post-operative diabetes, surgical extension,